Cohen Ilan, Nabriski Dan, Fishman Ami
Department of Obstetrics and Gynecology, Meir Medical Center, Kfar Saba, Israel, affiliated with Sackler Faculty of Medicine, Tel Aviv University, Israel.
Institute of Endocrinology, Diabetes and Metabolism, Meir Medical Center, Kfar Saba, Israel, affiliated with Sackler Faculty of Medicine, Tel Aviv University, Israel.
Gynecol Oncol Rep. 2015 Jun 10;15:12-5. doi: 10.1016/j.gore.2015.06.002. eCollection 2016 Jan.
The diagnosis of ovarian hormone-secreting neoplasm in postmenopausal women is currently based on imaging modalities and selective venography. However, these diagnostic tests are not always accurate. In order to improve and simplify the diagnosis, we propose a noninvasive hormonal test.
To report our experience using noninvasive hormonal test for the diagnosis of ovarian hormone producing tumor in two postmenopausal women.
Evaluation of androgen and estradiol serum levels following 1. Adrenal hormonal depression, 2. ovarian hormonal depression and 3. ovarian hormonal stimulation.
Tertiary care medical center.
Changes in androgen and estradiol levels.
In the first case, total testosterone, free androgen index and estradiol serum levels decreased following ovarian depression by GnRH-antagonist (6.9 nmol/L, 67 nmol/L and < 70 pmol/L, respectively) and subsequently increased after ovarian stimulation with LH (11.5 nmol/L, 117 nmol/L and 176 pmol/L, respectively). Histological evaluation revealed steroid cell tumor in one ovary. In the second case, estradiol serum levels decreased following ovarian depression by GnRH-antagonist (73 pmol/L) and subsequently increased following ovarian stimulation with FSH (118 pmol/L). Histological evaluation revealed granulosa cell tumor in one ovary.
To our knowledge, these are the first cases of ovarian hormone-producing tumors in postmenopausal women diagnosed by noninvasive hormonal test. The proposed test can be considered in postmenopausal women suspected of having androgen and/or estrogen producing tumors.
目前,绝经后女性卵巢激素分泌性肿瘤的诊断基于影像学检查和选择性静脉造影。然而,这些诊断测试并不总是准确的。为了改进和简化诊断,我们提出了一种非侵入性激素检测方法。
报告我们使用非侵入性激素检测诊断两名绝经后女性卵巢激素分泌肿瘤的经验。
在以下三种情况下评估血清雄激素和雌二醇水平:1. 肾上腺激素抑制;2. 卵巢激素抑制;3. 卵巢激素刺激。
三级医疗中心。
雄激素和雌二醇水平的变化。
在第一例中,使用GnRH拮抗剂抑制卵巢后,总睾酮、游离雄激素指数和血清雌二醇水平下降(分别为6.9 nmol/L、67 nmol/L和<70 pmol/L),随后用促黄体生成素刺激卵巢后升高(分别为11.5 nmol/L、117 nmol/L和176 pmol/L)。组织学评估显示一侧卵巢存在类固醇细胞瘤。在第二例中,使用GnRH拮抗剂抑制卵巢后,血清雌二醇水平下降(73 pmol/L),随后用促卵泡生成素刺激卵巢后升高(118 pmol/L)。组织学评估显示一侧卵巢存在颗粒细胞瘤。
据我们所知,这些是通过非侵入性激素检测诊断的绝经后女性卵巢激素分泌肿瘤的首例病例。对于怀疑患有雄激素和/或雌激素分泌肿瘤的绝经后女性,可以考虑采用本检测方法。